ZYMAR® (gatifloxacin ophthalmic solution) 0.3%
ZYMAR® is the first fourth-generation, topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis (commonly referred to as "pink eye") approved by the U.S. Food and Drug Administration (FDA). The FDA approved ZYMAR® in 2003 for the treatment of bacterial conjunctivitis caused by susceptible strains of Corynebacterium propinquum,* Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis,* Streptococcus pneumoniae, and Haemophilus influenzae. (*Efficacy for this organism was studied in fewer than 10 infections.)
ZYMAR® ophthalmic solution provides rapid and effective protection from bacteria that causes pink eye. In fact, ZYMAR® has been shown to quickly eradicate common pathogens in vitro (clinical significance unknown). Additionally, it is well-tolerated by patients and can be used in children as young as one year.
Important Safety Information
If an allergic reaction to gatifloxacin occurs, discontinue the drug. NOT FOR INJECTION. ZYMAR® ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs discontinue use and institute alternative therapy.
The most frequently reported adverse events occurring in 5-10 percent of patients were eye irritation, increased tearing, keratitis, and papillary conjunctivitis.